Similar articles

• Cost-benefit analysis of preventing sudden cardiac deaths with an implantable cardioverter defibrillator versus amiodarone.

  Caro JJ, Ward A, Deniz HB, O'Brien JA, Ehreth JL. Caro JJ, et al. Value Health. 2007 Jan-Feb;10(1):13-22. doi: 10.1111/j.1524-4733.2006.00140.x. Value Health. 2007. PMID: 17261112
• Impact of extending device longevity on the long-term costs of implantable cardioverter-defibrillator therapy: a modelling study with a 15-year time horizon.

  Boriani G, Braunschweig F, Deharo JC, Leyva F, Lubinski A, Lazzaro C. Boriani G, et al. Europace. 2013 Oct;15(10):1453-62. doi: 10.1093/europace/eut133. Epub 2013 May 21. Europace. 2013. PMID: 23696624
• How should we cost ICD therapy?

  Fox DJ, Davidson NC, Fitzpatrick AP. Fox DJ, et al. Int J Cardiol. 2007 May 16;118(1):1-3. doi: 10.1016/j.ijcard.2006.05.054. Epub 2007 Jan 25. Int J Cardiol. 2007. PMID: 17258335 No abstract available.
• ICD for primary prophylaxis of sudden cardiac death: an Indian perspective.

  Naik N, Juneja R. Naik N, et al. J Assoc Physicians India. 2007 Apr;55 Suppl:47-53. J Assoc Physicians India. 2007. PMID: 18376491 Review. No abstract available.
• The cost of implantable defibrillators: perceptions and reality.

  Camm J, Klein H, Nisam S. Camm J, et al. Eur Heart J. 2007 Feb;28(4):392-7. doi: 10.1093/eurheartj/ehl166. Epub 2006 Aug 3. Eur Heart J. 2007. PMID: 16887857 Review.